Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly Revenue of $251000.0 for Q1 2024, down 89.32% quarter-over-quarter from $2.4 million in Q4 2023.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Revenue for 2 consecutive years, with $251000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Revenue changed N/A year-over-year to $251000.0; the TTM figure through Dec 2024 stood at $251000.0 (changed N/A YoY), while the FY2024 annual figure was $251000.0, down 99.25% from the prior year.
- Revenue fell to $251000.0 in Q1 2024 per ARTV's latest filing, from $2.4 million in the prior quarter.
- Across five years, Revenue topped out at $26.7 million in Q3 2023 and bottomed at $251000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 251,000.00 |
| Dec 31, 2023 | 2.35 Mn |
| Sep 30, 2023 | 26.66 Mn |
| Jun 30, 2023 | 3.50 Mn |